Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2687790 | 0.87 | TSHR (0.56) | SMN1; SMN2TSHRRECQLLMNAALDH1A1 | |
| SCHEMBL3397034 | 0.86 | HPGD (0.58) | SMN1; SMN2TSHRGAALMNAALDH1A1 | |
| SCHEMBL14115754 | 0.83 | RECQL (0.47) | SMN1; SMN2TSHRRECQLLMNAALDH1A1 | |
| SCHEMBL5808629 | 0.82 | ALDH1A1 (0.59) | SMN1; SMN2TSHRGAALMNAALDH1A1 | |
| SCHEMBL1127232 | 0.82 | — | — | |
| SCHEMBL7977185 | 0.81 | TSHR (0.58) | SMN1; SMN2TSHRRECQLLMNAALDH1A1 | |
| SCHEMBL417400 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRRECQLLMNAALDH1A1 | |
| SCHEMBL13097124 | 0.81 | RECQL (0.49) | SMN1; SMN2TSHRRECQLLMNAALDH1A1 | |
| SCHEMBL18415359 | 0.80 | HPGD (0.68) | SMN1; SMN2TSHRRECQLLMNAALDH1A1 | |
| SCHEMBL2688840 | 0.80 | ALDH1A1 (0.60) | SMN1; SMN2TSHRGAALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3099675-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-12-07 | — | — | EP | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | disclosed |
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | disclosed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | DDT, BBOX1, IMPDH2 | SMN1; SMN2 1157/4885TSHR 4469/4885RECQL 2010/4885 |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | SMN1; SMN2 3768/4885TSHR 276/4885RECQL 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.